{"id":"https://openalex.org/W2808896775","doi":"https://doi.org/10.2337/db18-1886-p","title":"Praliciguat, a Clinical-Stage sGC Stimulator, Improved Glucose Tolerance and Insulin Sensitivity and Lowered Triglycerides in a Mouse Diet-Induced Obesity Model","display_name":"Praliciguat, a Clinical-Stage sGC Stimulator, Improved Glucose Tolerance and Insulin Sensitivity and Lowered Triglycerides in a Mouse Diet-Induced Obesity Model","publication_year":2018,"publication_date":"2018-06-22","ids":{"openalex":"https://openalex.org/W2808896775","doi":"https://doi.org/10.2337/db18-1886-p","mag":"2808896775"},"language":"en","primary_location":{"id":"doi:10.2337/db18-1886-p","doi":"https://doi.org/10.2337/db18-1886-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db18-1886-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091256737","display_name":"Chad D. Schwartzkopf","orcid":"https://orcid.org/0009-0001-0333-2807","observed_orcids":["https://orcid.org/0009-0001-0333-2807"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"CHAD D. SCHWARTZKOPF","raw_affiliation_strings":["Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029235888","display_name":"John R. Hadcock","orcid":"https://orcid.org/0000-0001-9719-1189","observed_orcids":["https://orcid.org/0000-0001-9719-1189"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"JOHN HADCOCK","raw_affiliation_strings":["Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103015775","display_name":"Juli E. Jones","orcid":"https://orcid.org/0000-0002-3870-1705","observed_orcids":["https://orcid.org/0000-0002-3870-1705"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"JULI E. JONES","raw_affiliation_strings":["Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111525044","display_name":"Mark G. Currie","orcid":"https://orcid.org/0009-0007-2239-5014","observed_orcids":["https://orcid.org/0009-0007-2239-5014"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"MARK CURRIE","raw_affiliation_strings":["Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110385743","display_name":"G. Todd Milne","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"GEORGE T. MILNE","raw_affiliation_strings":["Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge, MA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045236281","display_name":"Jaime L. Masferrer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"JAIME MASFERRER","raw_affiliation_strings":["Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge, MA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.8014,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.74598126,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":95},"biblio":{"volume":"67","issue":"Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.2863999903202057,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.2863999903202057,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.17550000548362732,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.07029999792575836,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/soluble-guanylate-cyclase-stimulator","display_name":"soluble guanylate cyclase stimulator","score":0.968999981880188},{"id":"https://openalex.org/keywords/nitric-oxide-cgmp-signaling","display_name":"nitric oxide/cGMP signaling","score":0.8040000200271606},{"id":"https://openalex.org/keywords/diet-induced-obesity","display_name":"diet-induced obesity","score":0.8209999799728394},{"id":"https://openalex.org/keywords/glucose-tolerance","display_name":"glucose tolerance","score":0.8960000276565552},{"id":"https://openalex.org/keywords/insulin-sensitivity","display_name":"insulin sensitivity","score":0.9789999723434448},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.9909999966621399},{"id":"https://openalex.org/keywords/triglycerides","display_name":"triglycerides","score":0.7940000295639038},{"id":"https://openalex.org/keywords/hepatic-triglycerides","display_name":"hepatic triglycerides","score":0.8640000224113464},{"id":"https://openalex.org/keywords/high-fat-diet","display_name":"high-fat diet","score":0.5659999847412109},{"id":"https://openalex.org/keywords/metabolic-effects","display_name":"metabolic effects","score":0.6579999923706055},{"id":"https://openalex.org/keywords/homa-ir","display_name":"HOMA-IR","score":0.7260000109672546},{"id":"https://openalex.org/keywords/fasting-insulin","display_name":"fasting insulin","score":0.5490000247955322},{"id":"https://openalex.org/keywords/mouse-model-of-obesity","display_name":"mouse model of obesity","score":0.6620000004768372},{"id":"https://openalex.org/keywords/drug-repurposing","display_name":"drug repurposing","score":0.621999979019165}],"concepts":[{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.8997290134429932},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.8735852241516113},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.6954854726791382},{"id":"https://openalex.org/C2776782570","wikidata":"https://www.wikidata.org/wiki/Q357439","display_name":"Adiponectin","level":4,"score":0.6514358520507812},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6119552850723267},{"id":"https://openalex.org/C2780994212","wikidata":"https://www.wikidata.org/wiki/Q422511","display_name":"Cyclic guanosine monophosphate","level":3,"score":0.5890553593635559},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.574912965297699},{"id":"https://openalex.org/C2779113265","wikidata":"https://www.wikidata.org/wiki/Q107525054","display_name":"Insulin tolerance test","level":5,"score":0.4987330436706543},{"id":"https://openalex.org/C2780833929","wikidata":"https://www.wikidata.org/wiki/Q1501412","display_name":"Glucose tolerance test","level":4,"score":0.448172003030777},{"id":"https://openalex.org/C2780613262","wikidata":"https://www.wikidata.org/wiki/Q223739","display_name":"Leptin","level":3,"score":0.447939932346344},{"id":"https://openalex.org/C519581460","wikidata":"https://www.wikidata.org/wiki/Q207843","display_name":"Nitric oxide","level":2,"score":0.4265795946121216},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.3045591413974762},{"id":"https://openalex.org/C3017594256","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin sensitivity","level":4,"score":0.20335936546325684}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/db18-1886-p","doi":"https://doi.org/10.2337/db18-1886-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db18-1886-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.5899999737739563,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2948579247","https://openalex.org/W4214814263","https://openalex.org/W3034246861","https://openalex.org/W3022547671","https://openalex.org/W4283465933","https://openalex.org/W4399372806","https://openalex.org/W4381337786","https://openalex.org/W4310376405","https://openalex.org/W3201200882","https://openalex.org/W2033522292"],"abstract_inverted_index":{"Background:":[0],"Praliciguat":[1,145,213],"(IW-1973)":[2],"is":[3],"a":[4,50,77,126,141,227],"soluble":[5],"guanylate":[6],"cyclase":[7],"(sGC)":[8],"stimulator":[9],"in":[10,49,104,197,226],"clinical":[11],"development.":[12],"In":[13],"animal":[14],"models,":[15],"praliciguat":[16,48,99],"has":[17,31],"broad":[18],"tissue":[19],"distribution":[20],"and":[21,38,133,161,181,210,219,223],"enhances":[22],"nitric":[23],"oxide":[24],"(NO)-cyclic":[25],"guanosine":[26],"monophosphate":[27],"(cGMP)":[28],"signaling,":[29],"which":[30],"been":[32],"shown":[33],"to":[34,76],"elicit":[35],"hemodynamic,":[36],"anti-inflammatory,":[37],"anti-fibrotic":[39],"effects.":[40],"This":[41],"study":[42],"assessed":[43],"the":[44,62,91,105,152],"metabolic":[45],"effects":[46],"of":[47,64,93,165],"mouse":[51,228],"DIO":[52],"model.":[53,231],"Methods:":[54],"Male":[55],"C57BL/6J":[56],"mice":[57,96,109,174],"(12":[58],"weeks":[59,87],"old":[60],"at":[61,84],"start":[63,92],"treatment)":[65],"were":[66,136],"either":[67,98],"maintained":[68],"on":[69,111],"regular":[70,112],"chow":[71],"(lean":[72],"mice)":[73],"or":[74,102],"switched":[75],"60%":[78],"high":[79],"fat":[80],"diet":[81],"(HFD)":[82],"starting":[83],"age":[85],"6":[86],"(obese":[88],"mice).":[89],"At":[90],"treatment,":[94],"obese":[95],"received":[97],"(6":[100],"mg/kg)":[101],"vehicle":[103,171,200],"HFD.":[106],"The":[107],"lean":[108],"remained":[110],"chow.":[113],"On":[114,129],"day":[115,130],"28,":[116],"an":[117,163],"oral":[118],"glucose":[119,149,217],"tolerance":[120],"test":[121],"(OGTT)":[122],"was":[123],"performed":[124],"after":[125,140],"3-h":[127,142],"fast.":[128,143],"29,":[131],"organs":[132],"terminal":[134],"blood":[135],"collected":[137],"for":[138],"analysis":[139],"Results:":[144],"treatment":[146],"lowered":[147],"OGTT":[148],"area":[150],"under":[151],"curve":[153],"(-22%,":[154],"P<0.05),":[155],"fasting":[156,182,192],"plasma":[157,206],"insulin":[158,166,215],"(-53%,":[159,168],"P<0.01)":[160,169,186],"HOMA-IR,":[162],"index":[164],"resistance":[167],"vs.":[170,187,199],"treatment.":[172],"Praliciguat-treated":[173],"also":[175],"had":[176],"lower":[177,221],"liver":[178,224],"(-36%,":[179],"P<0.05)":[180],"circulating":[183,222],"triglycerides":[184,225],"(-30%,":[185],"vehicle-treated":[188],"mice.":[189],"Furthermore,":[190],"several":[191],"biomarkers":[193],"did":[194],"not":[195],"change":[196],"treated":[198],"including":[201],"beta-hydroxybutyrate,":[202],"free":[203],"fatty":[204],"acids,":[205],"glucose,":[207],"cholesterol,":[208],"leptin,":[209],"adiponectin.":[211],"Conclusions:":[212],"improved":[214],"sensitivity,":[216],"tolerance,":[218],"yielded":[220],"diet-induced":[229],"obesity":[230],"Disclosure":[232],"C.D.":[233],"Schwartzkopf:":[234],"None.":[235,238,241],"J.":[236,269],"Hadcock:":[237],"J.E.":[239],"Jones:":[240],"M.":[242],"Currie:":[243],"Employee;":[244,251,261,271],"Self;":[245,252,257,272],"Ironwood":[246,253,258,273],"Pharmaceuticals,":[247,254,259,274],"Inc.":[248],"G.T.":[249],"Milne:":[250],"Inc..":[255,260,275],"Stock/Shareholder;":[256,265],"Spouse/Partner;":[262,266],"Catabasis":[263,267],"Pharmaceuticals.":[264,268],"Masferrer:":[270]},"counts_by_year":[{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2018-06-29T00:00:00"}